{
    "clinical_study": {
        "@rank": "75702", 
        "arm_group": [
            {
                "arm_group_label": "Catapres-TTS-3 crossover 1", 
                "arm_group_type": "Experimental", 
                "description": "subject to receive 0.3 mg/24 hr Catapres-TTS-3 Oppanol (T1) first, followed by Catapres-TTS-3 Vistanex (R1)"
            }, 
            {
                "arm_group_label": "Catapres-TTS-3 crossover 2", 
                "arm_group_type": "Experimental", 
                "description": "subject to receive  0.3 mg/24 hr Catapres-TTS-3 Vistanex (R1) first, followed by Catapres-TTS-3 Oppanol (T1)"
            }, 
            {
                "arm_group_label": "Catapres-TTS-1 crossover 1", 
                "arm_group_type": "Experimental", 
                "description": "subject to receive  0.1 mg/24 hr Catapres-TTS-1 with Oppanol (T2) and Vistanex (R2) simultaneously"
            }
        ], 
        "brief_summary": {
            "textblock": "To establish the bioequivalence and adhesion properties of transdermal clonidine prepared\n      with Oppanol\u00ae brands of polyisobutylene (PIB) vs. transdermal clonidine prepared with\n      VistanexTM brands of polyisobutylene (PIB) in healthy male and female volunteers."
        }, 
        "brief_title": "Bioequivalence of Two Transdermal Clonidine Administrations in Healthy Volunteers", 
        "completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          1. A complete medical history, including the physical examination, vital signs (BP, PR),\n             12-lead ECG, clinical laboratory tests\n\n          2. Age greater than or equal to 18 and Age less than or equal to 65 years\n\n          3. BMI greater than or equal to 18.5 and BMI  less than or equal to 32.0 kg/m2 (Body\n             Mass Index)\n\n          4. Signed and dated written informed consent prior to admission to the study\n\n          5. Male subjects, or females who meet any of the following criteria from at least 30\n             days before the first study drug administration and until 30 days after trial\n             completion:\n\n               -  Using adequate contraception, e.g. any of the following methods plus condom:\n                  implants, injectables, combined oral contraceptives, intrauterine device (IUD)\n\n               -  Sexually abstinent\n\n               -  Have a vasectomised sexual partner (vasectomy at least one year prior to\n                  enrolment)\n\n               -  Surgically sterilised (including hysterectomy)\n\n               -  Postmenopausal defined as at least one year of spontaneous amenorrhea\n\n        Exclusion criteria:\n\n          1. Any finding of the medical examination (including BP, PR and ECG) deviating from\n             normal\n\n          2. Repeated measurement of supine systolic blood pressure outside the range of 100-140\n             mm Hg or diastolic blood pressure outside the range of 60-90 mm Hg or pulse less than\n             55 bpm\n\n          3. Any subject with orthostatic hypotension at baseline screening exam\n\n          4. Any laboratory value outside the reference range\n\n          5. Any evidence of a clinically relevant concomitant disease\n\n          6. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic (including\n             insulin-dependent diabetes), immunological or hormonal disorders\n\n          7. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders\n             (such as depression) or neurological disorders (such as neuropathy)\n\n          8. History of relevant orthostatic hypotension, fainting spells or blackouts\n\n          9. Chronic or relevant acute infections\n\n         10. History of relevant allergy/hypersensitivity\n\n         11. Intake of drugs with a long half-life (greater than 24 hours) within at least one\n             month or less than 10 half-lives of the respective drug prior to administration or\n             during the trial.\n\n         12. Use of drugs which might reasonably influence the results of the trial within 10 days\n             prior to administration or during the trial\n\n         13. Participation in another trial with an investigational drug within two months prior\n             to administration or during the trial\n\n         14. Any concomitant therapy\n\n         15. Smoker\n\n         16. History of alcohol abuse\n\n         17. History of drug abuse\n\n         18. Blood donation\n\n         19. Excessive physical activities (within one week prior to administration or during the\n             trial)\n\n         20. Subjects should not swim during the treatment periods of the trial\n\n         21. Any condition of the skin, including eczema, psoriasis, or lymphedema, that involves\n             the upper arm in the area that would be utilized for application of the treatments\n\n         22. Pregnancy or planning to become pregnant within two months of study completion\n\n         23. Positive pregnancy test\n\n         24. A screening ECG that displays first-degree atrioventricular block (P-R interval >\n             0.20 seconds) or other conduction disturbance"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 24, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02096744", 
            "org_study_id": "253.2486"
        }, 
        "intervention": [
            {
                "arm_group_label": "Catapres-TTS-1 crossover 1", 
                "description": "Catapres-TTS-1 Oppanol", 
                "intervention_name": "Catapres-TTS-1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Catapres-TTS-3 crossover 1", 
                "description": "Catapres-TTS-3 Oppanol", 
                "intervention_name": "Intervention 1: Catapres-TTS-3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Catapres-TTS-3 crossover 2", 
                "description": "Catapres-TTS-3 Oppanol", 
                "intervention_name": "Intervention 1: Catapres-TTS-3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Catapres-TTS-3 crossover 2", 
                "description": "Catapres-TTS-3 Vistanex", 
                "intervention_name": "Intervention 2: Catapres-TTS-3", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Catapres-TTS-1 crossover 1", 
                "description": "Catapres-TTS-1 Vistanex", 
                "intervention_name": "Catapres-TTS-1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Catapres-TTS-3 crossover 1", 
                "description": "Catapres-TTS-3 Vistanex", 
                "intervention_name": "Intervention 2: Catapres-TTS-3", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clonidine"
        }, 
        "lastchanged_date": "May 28, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Austin", 
                    "country": "United States", 
                    "state": "Texas"
                }, 
                "name": "253.2486.1 Boehringer Ingelheim Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomized, Double-blind Study Designed to Assess the Bioequivalence and Adhesion Properties of Transdermal Clonidine-VistanexTM Compared to Transdermal Clonidine-Oppanol\u00ae Following Transdermal Administration in Healthy Male and Female Volunteers", 
        "overall_official": {
            "affiliation": "Boehringer Ingelheim", 
            "last_name": "Boehringer Ingelheim", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "AUC0-168 (area under the concentration-time curve of clonidine in plasma over the time interval from 0 to 168 h)", 
                "safety_issue": "No", 
                "time_frame": "up to 168 hours"
            }, 
            {
                "measure": "Cavg (average of measured concentrations of clonidine in plasma on Days 5, 6, and 7)", 
                "safety_issue": "No", 
                "time_frame": "on days 5, 6, and 7"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02096744"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "AUC0-8 (area under the concentration-time curve of clonidine in plasma over the time interval from 0 to infinity)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours"
            }, 
            {
                "measure": "Cmax (maximum concentration of clonidine in plasma)", 
                "safety_issue": "No", 
                "time_frame": "up to 240 hours"
            }
        ], 
        "source": "Boehringer Ingelheim", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Boehringer Ingelheim", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}